# MedExpansion

> Medical Intelligence at the core of innovation


## Posts

- [Antibody–Drug Conjugates (ADCs): How Antibody, Linker, and Payload Shape Efficacy and Safety](https://medexpansion.ch/antibody-drug-conjugates-adcs-how-antibody-linker-and-payload-shape-efficacy-and-safety/): ADCs were designed to selectively kill biomarker-positive cancer cells, but real-world results are complex. Learn why early clinical analysis is key to balancing efficacy, biomarker dependence, and chemo-like toxicity.
- [Antibody-Drug Conjugates (ADCs) Are Changing Biomarker-Driven Precision Oncology](https://medexpansion.ch/antibody-drug-conjugates-adcs-are-changing-biomarker-driven-precision-oncology/): ADCs disrupt the “biomarker = efficacy” model in precision medicine. Learn why payload, linker, and biomarker thresholds shape tumor selection, Phase 2 strategy, and clinical positioning.
- [Clinical strategy in oncology: rethink animal studies](https://medexpansion.ch/clinical-strategy-in-oncology-rethink-animal-studies/): Oncology is shifting fast. Base your clinical strategy on predictive cell testing, not animal studies. Identify the right tumors early and avoid dead ends.
- [Biotome and immunotherapy: a new predictive biomarker?](https://medexpansion.ch/biotome-and-immunotherapy-a-new-predictive-biomarker/): The biotome may impact response to immunotherapy. Could it become a new predictive biomarker in oncology? A look at recent scientific insights.
- [Rethinking phase 2 trials: beyond animal models](https://medexpansion.ch/rethinking-phase-2-trials-beyond-animal-models/): FDA’s exemption challenges phase 2 design in oncology. Should we move away from animal models and focus on early, cell-level clinical analysis?
- [FDA has eased preclinical requirements](https://medexpansion.ch/fda-has-eased-preclinical-requirements/): Good news for animal welfare: the FDA has eased preclinical requirements
- [Why choose your target tumors early in preclinical stage ?](https://medexpansion.ch/why-choose-your-target-tumors-early-in-preclinical-stage/): This simplified case study is inspired by real-world challenges
- [Immunotherapies and early-phase trials: what's next for phase 1/2?](https://medexpansion.ch/immunotherapies-and-early-phase-trials-whats-next-for-phase-1-2/): Immunotherapies have transformed cancer prognostic, and they’re reshaping early-phase clinical development too, demanding new strategies.
- [Biotech investor pitch: what CMOs really expect](https://medexpansion.ch/biotech-investor-pitch-what-cmos-really-expect/): Your pitch to investors is about your innovation. Great ! But what if they are expecting something else (the CMO speaking) ?
- [Designing oncology phase 2 early: start in vitro?](https://medexpansion.ch/tumor-agnostic-therapies-chasing-the-holy-grail-of-biomarkers/): In oncology, what if you design your phase 2 and the trajectory to phase 3 …. starting already from the in vitro stage ?
- [Microbiome in immuno-oncology: a silent phase 1/2 influencer?](https://medexpansion.ch/microbiome-in-immuno-oncology-a-silent-phase-1-2-influencer/): Can the microbiome silently impact immuno-oncology trials? Discover how it may influence your phase 1/2 study outcomes without being on your radar.
- [EMA/FDA oncology approvals: adapt early-phase strategy fast](https://medexpansion.ch/ema-fda-oncology-approvals-adapt-early-phase-strategy-fast/): One new EMA/FDA approval EVERY 5 MONTHS. This means faster changes in standards of care, and in future phase 3 comparators.
- [Immunotherapy earlier in cancer care: at what development cost?](https://medexpansion.ch/immunotherapy-earlier-in-cancer-care-at-what-development-cost/): Immunotherapy is no longer a last-resort option. It is now integrated earlier into cancer treatment, but at what cost for molecules in development?

## Pages

- [Legal Notice](https://medexpansion.ch/legal-notice/): MEDExpansion https://medexpansion.ch/ Identification and Publication The users of the website www.medexpansion.ch are hereby informed of the identity of the various parties involved in its creation and maintenance:This website is published by: Medexpansion Sàrl, whose registered office is located at Avenue Floréal 3, 1006 Lausanne.Phone number: +41 21 601 19 38N° registre commerce: CH-550.1.139.625-6Publishing Director: MR Alain Rinaldi Trademarks The trademarks and logos of the company Medexpansion Sàrl displayed on the site are registered trademarks and logos. Any total or partial reproduction of these trademarks and logos without the express permission of Medexpansion Sàrl is strictly prohibited. Hosting Hosting is provided by […]
- [Our method to de-risk development](https://medexpansion.ch/our-method-to-de-risk-development/): MEDExpansion Our method to de-risk development Sequential filters to find the quickest path to PoC Advanced cell tests now provide reliable insights into toxicity and biological behaviour for investigational molecules. Yet they can’t identify which tumours will best demonstrate your compound’s full clinical value in tomorrow’s treatment landscape. An early clinical analysis puts preclinical data in the perspective of future medical needs. It helps guide tumor selection for animal studies and, ultimately, for phase 2 trial, while ruling out early costly clinical dead ends A structured, experience-backed process to identify the best clinical path early, and accelerate and de-risk development […]
- [Strategic advisory for oncology start-ups - MedExpansion](https://medexpansion.ch/): MEDExpansion Strategic advisory for oncology start-ups External CMO with 30 + years’ experience, bringing strategic vision to de-risk and accelerate the roadmap from preclinical to clinical PoC Flexible CMO support Acting as your CMO, strategic and operational, tailored to your needs About me Sequential analysis methodology To focus resources on tumors with the highest potential for PoC and rule out early costly clinical dead ends More about Let’s Talk F: +41 79 624 79 55 M: a.rinaldi@medexpansion.ch The Sequential Analysis Method My structured sequential analysis bridges cell-stage results and tomorrow’s clinical reality : Advanced cell-test insights Seq2TraqTM matrix filter More targeted animal studies De-risked phase […]


[comment]: # (Generated by Hostinger Tools Plugin)